Quantifying and monitoring overdiagnosis in cancer screening: A systematic review of methods

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Carter, Jamie L ^a   Coletti, Russell J ^b   Harris, Russell P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER OVERDIAGNOSIS; CANCER SCREENING; COHORT ANALYSIS; COLORECTAL CANCER; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DISEASE MODEL; EVIDENCE BASED PRACTICE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERNAL VALIDITY; KIDNEY CANCER; LUNG CANCER; MELANOMA; METHODOLOGY; MONITORING; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RELIABILITY; RISK OF BIAS; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; THYROID CANCER; UTERUS CANCER; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; MASS SCREENING; NEOPLASMS; OBSERVATION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; TIME;

COHORT STUDIES; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; HUMANS; MASS SCREENING; NEOPLASMS; OBSERVATION; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84921328480     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g7773     Document Type: Article

References (67)

1. Black WC. Overdiagnosis: an underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst 2000;92:1280-2.
2. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13.
3. Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, et al. Women's views on overdiagnosis in breast cancer screening: a qualitative study. BMJ 2013;346:f158.
4. Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women's attitudes to false-positive mammography results and detection of ductal carcinoma in situ: cross-sectional survey. West J Med 2000;173:307.
5. De Bekker-Grob EW, Rose JM, Donkers B, Essink-Bot ML, Bangma CH, Steyerberg EW. Men's preferences for prostate cancer screening: a discrete choice experiment. Br J Cancer 2013;108:533-41.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
7. Harris R, Yeatts J, Kinsinger L. Breast cancer screening for women ages 50 to 69 years: a systematic review of observational evidence. Prev Med 2011;53:108-14.
8. US Preventive Services Task Force Procedure Manual. AHRQ publication no. 08-05118-EF. 2008. www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual.htm.
9. Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, et al. Grading the strength of a body of evidence when comparing medical interventions-agency for healthcare research and quality and the effective health care program. J Clin Epidemiol 2010;63:513-23.
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-94.
11. Davidov O, Zelen M. Overdiagnosis in early detection programs. Biostatistics 2004;5:603-13.
12. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulat R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83.
13. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 2013;158:145-53.
14. Gulati R, Inoue LY, Gore JL, Katcher J, Etzioni R. Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst 2014;106:djt367.
15. Heijnsdijk EAM, Der Kinderen A, Wever EM, Draisma G, Roobol MJ, De Koning HJ. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 2009;101:1833-8.
16. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. Can Med Assoc J 1998;159:1368-72.
17. Pashayan N, Duffy SW, Pharoah P, Greenberg D, Donovan J, Martin RM, et al. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer 2009;100:1198-204.
18. Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008;64:10-9.
19. Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med 2006;25:2846-66.
20. Wu GHM, Auvinen A, Maattanen L, Tammela TLJ, Stenman UH, Hakama M, et al. Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. Int J Cancer 2012;131:1367-75.
21. De Gelder R, Fracheboud J, Heijnsdijk EAM, den Heeten G, Verbeek ALM, Broeders MJM, et al. Digital mammography screening: weighing reduced mortality against increased overdiagnosis. Prev Med 2011;53:134-40.
22. De Gelder R, Heijnsdijk EAM, Van Ravesteyn NT, Fracheboud J, Draisma G, De Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev 2011;33:111-21.
23. Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Björneld L, et al. Estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res 2005;7:258-65.
24. Gunsoy NB, Garcia-Closas M, Moss SM. Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom. Breast Cancer Res 2012;14:R152.
25. Martinez-Alonso M, Vilaprinyo E, Marcos-Gragera R, Rue M. Breast cancer incidence and overdiagnosis in Catalonia (Spain). Breast Cancer Res 2010;12:R58.
26. Olsen AH, Jensen A, Njor SH, Villadsen E, Schwartz W, Vejborg I, et al. Breast cancer incidence after the start of mammography screening in Denmark. Br J Cancer 2003;88:362-5.
27. Seigneurin A, Francois O, Labarere J, Oudeville P, Monlong J, Colonna M. Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ 2011;343:d7017.
28. Duffy SW, Field JK, Allgood PC, Seigneurin A. Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom. Br J Cancer 2014;110:1834-40.
29. Hazelton WD, Goodman G, Rom WN, Tockman M, Thornquist M, Moolgavkar S, et al. Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers. Math Biosci 2012;240:20-34.
30. Pinsky PF. An early- and late-stage convolution model for disease natural history. Biometrics 2004;60:191-8.
31. Luo D, Cambon AC, Wu D. Evaluating the long-term effect of FOBT in colorectal cancer screening. Cancer Epidemiol 2012;36:e54-60.
32. Zahl PH, Jorgensen KJ, Gotzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. Br J Cancer 2013;109:2014-9.
33. Dominioni L, Rotolo N, Mantovani W, Poli A, PIsani S, Conti V, et al. A population-based cohort study of chest x-ray screening in smokers: Lung cancer detection findings and follow-up. BMC Cancer 2012;12:18.
34. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Tazelaar HD, et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology 2007;242:555-62.
35. Sobue T, Suzuki T, Matsuda M, Kuroishi T, Ikeda S, Naruke T. Survival for clinical stage I lung cancer not surgically treated: comparison between screen-detected and symptom-detected cases. Cancer 1992;69:685-92.
36. Sone S, Nakayama T, Honda T, Tsushima K, Li F, Haniuda M, et al. Long-term follow-up study of a population-based 1996-1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography. Lung Cancer 2007;58:329-41.
37. Veronesi G, Maisonneuve P, Bellomi M, Rampinelli C, Durli I, Bertolotti R, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med 2012;157:776-84.
38. Yankelevitz DF, Kostis WJ, Henschke CI, Heelan RT, Libby DM, Pasmantier MW, et al. Overdiagnosis in chest radiographic screening for lung carcinoma: frequency. Cancer 2003;97:1271-5.
39. Graif T, Loeb S, Roehl KA, Gashti SN, Griffin C, Yu X, et al. Under diagnosis and over diagnosis of prostate cancer. J Urol 2007;178:88-92.
40. Pelzer AE, Colleselli D, Bektic J, Schaefer G, Ongarello S, Schwentner C, et al. Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference? BJU Int 2008;102:24-7.
41. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. New Engl J Med 2012;367:1998-2005.
42. Coldman A, Phillips N. Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program. CMAJ 2013;185:E492-8.
43. Duffy SW, Tabar L, Olsen AH, Vitak B, Allgood PC, Chen THH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen 2010;17:25-30.
44. Falk RS, Hofvind S, Skaane P, Haldorsen T. Overdiagnosis among women attending a population-based mammography screening program. Int J Cancer 2013;133:705-12.
45. Hellquist BN, Duffy SW, Nystrom L, Jonsson H. Overdiagnosis in the population-based service screening programme with mammography for women aged 40 to 49 years in Sweden. J Med Screen 2012;19:14-9
46. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009;339:b2587.
47. Jorgensen KJ, Zahl PH, Gotzsche PC. Overdiagnosis in organised mammography screening in Denmark. a comparative study. BMC Women's Health 2009;9:36.
48. Junod B, Zahl PH, Kaplan RM, Olsen J, Greenland S. An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts. BMC Cancer 2011;11:401.
49. Kalager M, Adami H, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening. Ann Intern Med 2012;157:221-2.
50. Morrell S, Barratt A, Irwig L, Howard K, Biesheuvel C, Armstrong B. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. Cancer Causes Control 2010;21:275-82.
51. Njor SH, Olsen AH, Blichert-Toft M, Schwartz W, Vejborg I, Lynge E. Overdiagnosis in screening mammography in Denmark: population based cohort study. BMJ 2013;346:f1064.
52. Paci E, Miccinesi G, Puliti D, Baldazzi P, De Lisi V, Falcini F, et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Res 2006;8:R68.
53. Peeters PHM, Verbeek ALM, Straatman H, Holland R, Hendriks JHCL, Mravunac M, et al. Evaluation of overdiagnosis of breast cancer in screening with mammography: results of the Nijmegen programmme. Int J Epidemiol 1989;18:295-9.
54. Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer 2009;45:3166-71.
55. Puliti D, Miccinesi G, Zappa M, Manneschi G, Crocetti E, Paci E. Balancing harms and benefits of service mammography screening programs: a cohort study. Breast Cancer Res 2012;14:R9
56. Svendsen AL, Olsen AH, Von Euler-Chelpin M, Lynge E. Breast cancer incidence after the introduction of mammography screening: what should be expected? Cancer 2006;106:1883-90.
57. Zahl PH, Strand BH, Maeshlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004;328:921-4.
58. Zahl PH, Maehlen J. Overdiagnosis of breast cancer after 14 years of mammography screening. Tidsskr Nor Legeforen 2012;132:414-7.
59. Ciatto S, Gervasi G, Bonardi R, Frullini P, Zendron P, Lombardi C, et al. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur J Cancer 2005;41:411-5.
60. Zappa M. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence screening pilot study. Ann Oncol 1998;9:1297-300.
61. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ 2006;332:689-91.
62. Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014;174:269-74.
63. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 2014;348:g366.
64. Welch HG, Schwartz LM, Woloshin S. Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers. BMJ 2006;332:727.
65. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol 2007;8:1129-38.
66. Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 2012;19(suppl 1):42-56.
67. Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med 2013;158:831-8.